EyePoint Pharmaceuticals, Inc. has been the subject of a Schedule 13G filing with the Securities and Exchange Commission, indicating a significant investment by Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross. The filing, dated April 30, 2024, reports that Adage Capital Management, L.P., along with Atchinson and Gross, collectively hold 5,156,299 shares of EyePoint Pharmaceuticals' common stock, which represents 10.35% of the company's class of securities. This level of ownership classifies them as major shareholders, as they own more than 5% of the company's common stock. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, which is typically used by passive investors. The address for the principal business office of the reporting persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. The filing emphasizes that the acquisition of the shares is in the ordinary course of business and not with the purpose of changing or influencing the control of EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals, Inc. has been the subject of a Schedule 13G filing with the Securities and Exchange Commission, indicating a significant investment by Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross. The filing, dated April 30, 2024, reports that Adage Capital Management, L.P., along with Atchinson and Gross, collectively hold 5,156,299 shares of EyePoint Pharmaceuticals' common stock, which represents 10.35% of the company's class of securities. This level of ownership classifies them as major shareholders, as they own more than 5% of the company's common stock. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, which is typically used by passive investors. The address for the principal business office of the reporting persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. The filing emphasizes that the acquisition of the shares is in the ordinary course of business and not with the purpose of changing or influencing the control of EyePoint Pharmaceuticals.